Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMDW) Research & Development (2019 - 2025)

Historic Research & Development for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to $262.5 million.

  • Revolution Medicines' Research & Development rose 7298.36% to $262.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $880.5 million, marking a year-over-year increase of 5916.62%. This contributed to the annual value of $592.2 million for FY2024, which is 3995.83% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Research & Development is $262.5 million, which was up 7298.36% from $224.1 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Research & Development peaked at $262.5 million during Q3 2025, and registered a low of $40.9 million during Q1 2021.
  • In the last 5 years, Revolution Medicines' Research & Development had a median value of $98.0 million in 2023 and averaged $113.1 million.
  • The largest annual percentage gain for Revolution Medicines' Research & Development in the last 5 years was 12453.91% (2023), contrasted with its biggest fall of 2205.17% (2023).
  • Over the past 5 years, Revolution Medicines' Research & Development (Quarter) stood at $53.7 million in 2021, then increased by 23.19% to $66.1 million in 2022, then skyrocketed by 124.54% to $148.5 million in 2023, then grew by 26.68% to $188.1 million in 2024, then surged by 39.56% to $262.5 million in 2025.
  • Its Research & Development was $262.5 million in Q3 2025, compared to $224.1 million in Q2 2025 and $205.7 million in Q1 2025.